isabelobrien, Author at European Medical Journal - Page 20 of 70

Bradley Monk

Onc Now: Episode 18: What's New from ESGO 2025?

Bradley Monk, Medical Director of Late-Phase Research at Florida Cancer Specialists, shares his insights from ESGO 2025 and landmark studies in gynaecologic oncology.

Paolo Gallipoli

Hema Now: Episode 17: What Drives Change in Leukaemia Cells?

Paolo Gallipoli, Clinical Reader, Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London joins the podcast to discuss the biology, onset, and treatment of myeloid leukaemias.

British government buildings

BioNTech commits £1bn to UK in landmark life sciences investment

BioNTech is set to invest up to £1bn in the UK over the next decade, establishing new R&D and AI hubs.

West Nile Virus found in UK mosquitoes for first time

Experts have pointed to the climate crisis as a potential trigger of the West Nile Virus finding.

Medical affairs: What's working for HCPs in 2025

Four medical affairs leaders reveal what’s working (and what’s not) when it comes to engaging time-starved HCPs in 2025.

The world

WHO chief reveals action on pandemics, climate and AMR

Dr Tedros sets out WHO’s next steps on pandemic preparedness, climate action and AMR during the 78th World Health Assembly in Geneva.

Charl van Zyl, Dr Dennise Broderick, Christoph von Der Goltz and Rebecca Vermeulen

Season 9 highlights: GOLD Medal Moments

Look back on Season 9’s GOLD Medal Moments with the team before Season 10 begins.

Colorectal cancer leads in real-world data, says Phesi

Colorectal cancer now has the most real-world data, but Phesi warns clinical trials are lagging behind.

Portrait of Andrew Cooper

5 minutes with Andrew Cooper, CEO, CluePoints

Discover Andrew Cooper’s passion for optimising clinical trials with AI, driving innovation and building a culture of teamwork and purpose.

Joan Carles

Onc Now: Episode 17: Breaking New Ground in Genitourinary Cancer Treatment

Joan Carles, Vall d’Hebron, shares insights on anti-angiogenic therapies, resistance in GU cancers, and the future of personalised oncology.